ישראל - עברית - Ministry of Health

meridian bioscience isreal ltd., israel - urea- c 13 - טבליה - urea- c 13 75 mg - intended for use in the qualitative detection of urease associated with h. pylory in the human stomach and as an aid in the initial diagnosis and post treatment monitoring of h. pylory infection in adult patients.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.

ישראל - עברית - Ministry of Health

medison pharma ltd - pemigatinib - טבליה - pemigatinib 13.5 mg - pemigatinib

ישראל - עברית - Ministry of Health

דניה קוסמטיקס בעמ - איפור שפתיים

ישראל - עברית - Ministry of Health

rafa laboratories ltd - dry extract from cimicifugae rhizoma (black cohosh) - טבליה - dry extract from cimicifugae rhizoma (black cohosh) 13 mg - cimicifugae rhizoma

ישראל - עברית - Ministry of Health

חומרים ותכשירים קוסמטיים - החלקת שיער

ישראל - עברית - Ministry of Health

חומרים ותכשירים קוסמטיים - החלקת שיער

ישראל - עברית - Ministry of Health

בי אס בודי אנד סול - הזנה לשיער

ישראל - עברית - Ministry of Health

בי אס בודי אנד סול - החלקת השיער

ישראל - עברית - Ministry of Health

בי אס בודי אנד סול - החלקת השיער